NAMS on Nasdaq
NewAmsterdam Pharma Co N.V.
Pharmaceutical preparations company, listed on Nasdaq (NAMS).
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with NextCure, Inc., CAPRICOR THERAPEUTICS, INC. or Prenetics Global Ltd, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development57¢$141.8M
- Selling, general and admin43¢$106.4M
Out of $22.5M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M |
| Research and development expenses | $141.8M | $151.4M | $159.4M |
| Selling, general and administrative expenses | $106.4M | $70.4M | $37.6M |
| Total operating expenses | $248.2M | $221.9M | $197.1M |
| Operating loss | -$225.7M | -$176.3M | -$183.0M |
| Interest income | $27.6M | $16.9M | $11.3M |
| Fair value change - earnout | $4.0M | -$37.0M | -$266.0K |
| Fair value change - warrants | -$22.8M | -$38.6M | -$10.0M |
| Foreign exchange gains/(losses) | $13.1M | -$6.6M | $5.1M |
| Loss before tax | -$203.8M | -$241.6M | -$176.9M |
| Income tax expense (benefit) | -$1.0K | $27.0K | |
| Loss for the year | -$203.8M | -$241.6M | -$176.9M |
| Unrealized gain on available-for-sale securities, net of tax | $326.0K | $45.0K | |
| Total comprehensive loss for the year, net of tax | -$203.5M | -$241.6M | -$176.9M |
| Basic | -$1.72 | -$2.56 | -$2.15 |
| Diluted | -$1.72 | -$2.56 | -$2.15 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-07-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $490.0M | $771.7M | $340.4M | ||
| Prepayments and other receivables | $38.1M | $24.3M | |||
| Employee receivables | $5.0M | ||||
| Marketable securities, current | $146.2M | $62.4M | |||
| Restricted cash | $1.3M | ||||
| Total current assets | $675.7M | $863.4M | |||
| Marketable securities, net of current portion | $92.6M | ||||
| Property, plant and equipment, net | $383.0K | $242.0K | |||
| Operating right of use asset | $185.0K | $431.0K | |||
| Intangible assets | $407.0K | $534.0K | |||
| Total assets | $769.3M | $864.6M | |||
| Accounts payable | $9.0M | $4.7M | |||
| Accrued expenses and other current liabilities | $15.4M | $13.6M | |||
| Deferred revenue, current | $4.0M | $6.0M | |||
| Lease liability, current | $136.0K | $246.0K | |||
| Derivative earnout liability, current | $44.8M | ||||
| Derivative warrant liabilities | $57.3M | $37.5M | |||
| Total current liabilities | $85.8M | $106.9M | |||
| Lease liability, net of current portion | $66.0K | $202.0K | |||
| Total liabilities | $85.9M | $107.1M | |||
| Ordinary shares | $14.3M | $13.4M | |||
| Additional paid-in capital | $1.4B | $1.3B | |||
| Accumulated loss | -$762.4M | -$558.6M | |||
| Accumulated other comprehensive income | $4.8M | $4.5M | |||
| Total shareholders' equity | $683.4M | $757.5M | $288.4M | $430.1M | |
| Total liabilities and shareholders' equity | $769.3M | $864.6M | |||
| Ordinary shares, par value | 0.12 EUR | 0.12 EUR | 0.12 EUR | ||
| Ordinary shares, authorized | 400.0M shares | 400.0M shares | |||
| Ordinary shares, issued | 114.4M shares | 108.1M shares | |||
| Ordinary shares, outstanding | 114.4M shares | 108.1M shares | 36.3M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-07-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $490.0M | $771.7M | $340.4M | ||
| Prepayments and other receivables | $38.1M | $24.3M | |||
| Employee receivables | $5.0M | ||||
| Marketable securities, current | $146.2M | $62.4M | |||
| Restricted cash | $1.3M | ||||
| Total current assets | $675.7M | $863.4M | |||
| Marketable securities, net of current portion | $92.6M | ||||
| Property, plant and equipment, net | $383.0K | $242.0K | |||
| Operating right of use asset | $185.0K | $431.0K | |||
| Intangible assets | $407.0K | $534.0K | |||
| Total assets | $769.3M | $864.6M | |||
| Accounts payable | $9.0M | $4.7M | |||
| Accrued expenses and other current liabilities | $15.4M | $13.6M | |||
| Deferred revenue, current | $4.0M | $6.0M | |||
| Lease liability, current | $136.0K | $246.0K | |||
| Derivative earnout liability, current | $44.8M | ||||
| Derivative warrant liabilities | $57.3M | $37.5M | |||
| Total current liabilities | $85.8M | $106.9M | |||
| Lease liability, net of current portion | $66.0K | $202.0K | |||
| Total liabilities | $85.9M | $107.1M | |||
| Ordinary shares | $14.3M | $13.4M | |||
| Additional paid-in capital | $1.4B | $1.3B | |||
| Accumulated loss | -$762.4M | -$558.6M | |||
| Accumulated other comprehensive income | $4.8M | $4.5M | |||
| Total shareholders' equity | $683.4M | $757.5M | $288.4M | $430.1M | |
| Total liabilities and shareholders' equity | $769.3M | $864.6M | |||
| Ordinary shares, par value | 0.12 EUR | 0.12 EUR | 0.12 EUR | ||
| Ordinary shares, authorized | 400.0M shares | 400.0M shares | |||
| Ordinary shares, issued | 114.4M shares | 108.1M shares | |||
| Ordinary shares, outstanding | 114.4M shares | 108.1M shares | 36.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Loss for the year | -$203.8M | -$241.6M | -$176.9M |
| Depreciation and amortization | $220.0K | $113.0K | $49.0K |
| Non-cash rent expense | $12.0K | $6.0K | |
| Fair value change - derivative earnout and warrants | $18.8M | $75.6M | $10.3M |
| Loss on disposal of property, plant and equipment | $12.0K | ||
| Foreign exchange (gains)/losses | -$13.1M | $6.6M | -$5.1M |
| Amortization of premium/discount on available-for-sale debt securities | -$1.4M | -$227.0K | |
| Share-based compensation | $59.4M | $33.6M | $24.6M |
| Changes in prepayments (current and non-current) and other receivables | -$13.3M | -$17.5M | $4.0M |
| Changes in accounts payable | $4.9M | -$12.9M | $5.1M |
| Changes in accrued expenses and other current liabilities | $2.4M | $1.7M | $5.5M |
| Changes in deferred revenue | -$2.0M | -$4.0M | -$8.7M |
| Net cash used in operating activities | -$147.8M | -$158.6M | -$141.2M |
| Purchase of property, plant and equipment, including internal use software | -$246.0K | -$672.0K | -$24.0K |
| Maturities of marketable securities | $122.1M | ||
| Purchases of marketable securities | -$296.7M | -$62.2M | |
| Net cash used in investing activities | -$174.9M | -$62.8M | -$24.0K |
| Proceeds from exercise of warrants | $1.6M | $13.8M | $8.6M |
| Proceeds from exercise of options | $29.5M | $1.8M | $290.0K |
| Payment of withholding taxes related to net share settlement of exercised options | -$989.0K | ||
| Net cash provided by financing activities | $29.5M | $659.5M | $8.9M |
| Net change in cash, cash equivalents and restricted cash | -$293.2M | $438.1M | -$132.3M |
| Foreign exchange differences | $12.8M | -$6.8M | $5.1M |
| Recognition of ROU asset | $562.0K | ||
| Issuance of earnout shares | $40.8M | ||
| Cash paid for income taxes | $1.0K | $27.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led NewAmsterdam Pharma Co N.V., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerMichael H. Davidson Dec 29, 2023 to now9
- Chief financial officerMayur Ian Somaiya Dec 29, 2023 to now10
- Chief operating officerDouglas F. Kling Dec 29, 2023 to now11
Board members and other officers (16)
- Vice President, ControllerRobert William Gunning Aug 14, 2026 to now12
- Chief Business OfficerJuliette Berangere Audet Apr 2, 2024 to now13
- Chief Commercial OfficerWilliam A. Jones Jr. May 3, 2024 to Jan 7, 202514
- Chief Scientific OfficerJohannes Jacob Pieter Kastelein Dec 29, 2023 to now15
- Chief Accounting OfficerLouise Frederika Kooij Dec 29, 2023 to now16
- Board memberAdele M. Gulfo Apr 17, 2025 to now17
- Board memberMark C. McKenna Jul 19, 2024 to now18
- Board memberWouter Joustra Jul 19, 2024 to Jul 19, 202419
- Board memberHugo Alexander Slootweg Dec 29, 2023 to Dec 29, 202320
- Board memberJames N. Topper Dec 29, 2023 to now21
- Board memberJohannes Jacob Pieter Kastelein Dec 29, 2023 to now15
- Board memberJohn W. Smither Dec 29, 2023 to now22
- Board memberJuliette Berangere Audet Dec 29, 2023 to Dec 29, 202323
- Board memberLouis G. Lange Dec 29, 2023 to now24
- Board memberMichael H. Davidson Dec 29, 2023 to now9
- Board memberNicholas Downing Dec 29, 2023 to Dec 29, 202325
Former names
- NewAmsterdam Pharma Co B.V.Aug 4, 2022 to Nov 22, 20222
Timeline
- Dec 29, 2023New chief executive Michael H. Davidson becomes CEO9
Filings
412 filings to the SEC since October 2021: 6 annual reports, 8 quarterly reports, 49 major events, 132 insider forms, 42 large holders, 175 other. The latest 20:
- Oct 2, 20264 EDGAR
- Sep 29, 20268-K EDGAR
- Sep 22, 2026SCHEDULE 13D/A EDGAR
- Sep 21, 20268-K EDGAR
- Sep 15, 20264 EDGAR
- Sep 9, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Aug 25, 2026144/A EDGAR
- Aug 25, 20264 EDGAR
- Aug 24, 2026144 EDGAR
- Aug 14, 20268-K/A EDGAR
- Aug 14, 20263 EDGAR
- Aug 14, 20268-K EDGAR
- Aug 6, 2026SCHEDULE 13G/A EDGAR
- Aug 5, 20268-K EDGAR
- Aug 5, 202610-Q EDGAR
- Jul 24, 20268-K EDGAR
- Jul 22, 20268-K EDGAR
- Jul 22, 20264 EDGAR
- Jun 24, 20264 EDGAR
The 412 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 42 such filings since October 2021, the latest 10:
- Sep 22, 2026SCHEDULE 13D/A
- Aug 6, 2026SCHEDULE 13G/A
- Jun 4, 2026SCHEDULE 13G/A
- May 14, 2026SCHEDULE 13D/A
- May 6, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Feb 5, 2026SCHEDULE 13G
- Dec 4, 2025SCHEDULE 13D/A
- Nov 13, 2025SCHEDULE 13G/A
- Nov 7, 2025SCHEDULE 13D/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARAdele M. Gulfo, Board member
- 18SEC EDGARMark C. McKenna, Board member
- 19SEC EDGARWouter Joustra, Board member
- 20
- 21SEC EDGARJames N. Topper, Board member
- 22SEC EDGARJohn W. Smither, Board member
- 23
- 24SEC EDGARLouis G. Lange, Board member
- 25SEC EDGARNicholas Downing, Board member